CNTG - Centogene Alector initiate EFRONT study in frontotemporal dementia

Centogene N.V. (CNTG) announces a new observational study to understand the prevalence of genetic mutations in patients with frontotemporal dementia ((FTD)).The observational EFRONT Study is being conducted with Alector (ALEC) under a commercial agreement.Financial details of the deal are not disclosed. The study aims to enroll and genetically test more than 3,000 FTD patients at participating centers in Belgium, Germany, Greece, Italy, Portugal, Spain, and Turkey. FTD is a rapidly progressing and severe form of dementia found mostly in patients under the age of 65 at the time of diagnosis.

For further details see:

Centogene, Alector initiate EFRONT study in frontotemporal dementia